Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and is susceptible to develop gemcitabine (GEM) resistance. Decreased expression of human equilibrative nucleoside transporter 1 (hENT1) accompanied by compensatory increase of glycolysis is strongly associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Yue, Li, Ting, Xi, Yun, Zeng, Xinyi, Miao, Ying, Guo, Rui, Zhang, Min, Li, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438150/
https://www.ncbi.nlm.nih.gov/pubmed/36050724
http://dx.doi.org/10.1186/s12935-022-02681-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438150/
https://www.ncbi.nlm.nih.gov/pubmed/36050724
http://dx.doi.org/10.1186/s12935-022-02681-0

Ejemplares similares